Yoshihiko Satoh
Fujisawa, 2510012, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Discovery of Rogocekib (CTX-712): A Potent and Selective CLK Inhibitor for Cancer Treatment.
Journal: ACS medicinal chemistry letters
Published: July 04, 2025
Design and synthesis of a monocyclic derivative as a selective ACC1 inhibitor by chemical modification of biphenyl ACC1/2 dual inhibitors.
Journal: Bioorganic & medicinal chemistry
Published: December 08, 2020
The identification and pharmacological evaluation of potent, selective and orally available ACC1 inhibitor.
Journal: Bioorganic & medicinal chemistry letters
Published: August 17, 2019
Design and synthesis of a novel 1H-pyrrolo[3,2-b]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor.
Journal: Bioorganic & medicinal chemistry
Published: February 18, 2019
Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors.
Journal: Journal of medicinal chemistry
Published: December 13, 2017
Discovery of Novel 5-(Piperazine-1-carbonyl)pyridin-2(1H)-one Derivatives as Orally eIF4A3-Selective Inhibitors.
Journal: ACS medicinal chemistry letters
Published: July 13, 2017
Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitors as Anticancer Agents.
Journal: Bioorganic & medicinal chemistry
Published: February 01, 2017
In vitro and in vivo antitumor activities of T-3764518, a novel and orally available small molecule stearoyl-CoA desaturase 1 inhibitor.
Journal: European journal of pharmacology
Published: January 11, 2017
Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine.
Journal: Molecular oncology
Published: January 10, 2017
Synthesis and evaluation of hedgehog signaling inhibitor with novel core system.
Journal: Bioorganic & medicinal chemistry
Published: April 01, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026